Abstract
A 40 years old male with colorectal cancer, with an unbalanced hypercaloric diet, attempted, on his own initiative, to gain weight, without nutritional follow-up, during chemotherapy treatment with oxaliplatin protocols, without pharmaceutical guidance. When initiating the new protocol, with oxaliplatin/irinotecan combination therapy, he presented symptomatology suggestive of hepatic injury during the administration of oxaliplatin. When performing a Magnetic Resonance Imaging of the total abdomen, hepatic nodules were identified indicating lesions resulting from the chemotherapy treatment, and blood tests indicated Aspartate aminotransferase levels in 55 U/L and Alanine aminotransferase in 68 U/L. The patient underwent partial hepatectomy for the removal of the nodules and was currently in clinical care, presenting a frame stable but non-therapeutic possibility. This case highlights the importance of interaction among health professionals, reinforcing the need for multiprofessional approaches to better patient response to antineoplastic treatment.
Keywords: Antineoplastic agents, chemical and drug-induced liver injury, combination, drug therapy, drug-related side effects and adverse reactions, hepatotoxicity, overnutrition, oxaliplatin.
Graphical Abstract
[1]
Brasil. Ministério da Saúde Instituto Nacional de Câncer – INCA Estimativa de 2016.Disponível em:. http://www.inca.gov.br/ estimativa/2016/tbregioes_consolidado.asp Acesso em: 12 nov 2016.
[2]
Martins CG, Wagner SC, Linder R. Individualização Farmacocinética das Doses de 5-Fluoruracil no Câncer Colorretal. Rev Bras Cancerol 2013; 59(2): 271-80.
[3]
Cavalcanti IDL, Santos RJ, Cordeiro RP. Evolução conceitual da biossegurança na manipulação de antineoplásicos. Electron J Pharm 2016; 13(1): 6-17.
[http://dx.doi.org/10.5216/ref.v13i1.31435]
[http://dx.doi.org/10.5216/ref.v13i1.31435]
[4]
Kalil AN, Coral GP, Santos FAI, Gonzalez MC, Neutzling CB. The association between preoperative chemotherapy and the prevalence of hepatic steatosis in hepatectomy for metastatic colorectal cancer. Arq Bras Cir Dig 2014; 27(2): 120-5.
[http://dx.doi.org/10.1590/S0102-67202014000200008] [PMID: 25004290]
[http://dx.doi.org/10.1590/S0102-67202014000200008] [PMID: 25004290]
[5]
Agius L. High-carbohydrate diets induce hepatic insulin resistance to protect the liver from substrate overload. Biochem Pharmacol 2013; 85(3): 306-12.
[http://dx.doi.org/10.1016/j.bcp.2012.09.019] [PMID: 23022226]
[http://dx.doi.org/10.1016/j.bcp.2012.09.019] [PMID: 23022226]
[6]
Brown KGM, Solomon MJ, Mahon K, O’Shannassy S. Management of colorectal cancer. BMJ 2019; 366: l4561-7.
[http://dx.doi.org/10.1136/bmj.l4561] [PMID: 31439545]
[http://dx.doi.org/10.1136/bmj.l4561] [PMID: 31439545]
[7]
García-Alfonso P, Ferrer A, Gil S, et al. Neoadjuvant and conversion treatment of patients with colorectal liver metastasis: the potential role of bevacizumab and other antiangiogenic agents. Target Oncol 2015; 10(4): 453-65.
[http://dx.doi.org/10.1007/s11523-015-0362-0] [PMID: 25752908]
[http://dx.doi.org/10.1007/s11523-015-0362-0] [PMID: 25752908]
[8]
Gelen V, Sengul E, Gedikli S, Atila G, Uslu H, Makav M. The protective effect of rutin and quercetin on 5-FU-induced hepatotoxicity in rats. Asian Pac J Trop Biomed 2017; 7(7): 647-53.
[http://dx.doi.org/10.1016/j.apjtb.2017.06.013]
[http://dx.doi.org/10.1016/j.apjtb.2017.06.013]
[9]
Labbe G, Pessayre D, Fromenty B. Drug-induced liver injury through mitochondrial dysfunction: mechanisms and detection during preclinical safety studies. Fundam Clin Pharmacol 2008; 22(4): 335-53.
[http://dx.doi.org/10.1111/j.1472-8206.2008.00608.x] [PMID: 18705745]
[http://dx.doi.org/10.1111/j.1472-8206.2008.00608.x] [PMID: 18705745]
[10]
Cai Z, Yang J, Shu X, Xiong X. Chemotherapy-associated hepatotoxicity in colorectal cancer. J BUON 2014; 19(2): 350-6.
[PMID: 24965391]
[PMID: 24965391]
[11]
Chun YS, Laurent A, Maru D, Vauthey JN. Management of chemotherapy-associated hepatotoxicity in colorectal liver metastases. Lancet Oncol 2009; 10(3): 278-86.
[http://dx.doi.org/10.1016/S1470-2045(09)70064-6] [PMID: 19261256]
[http://dx.doi.org/10.1016/S1470-2045(09)70064-6] [PMID: 19261256]
[12]
McWhirter D, Kitteringham N, Jones RP, Malik H, Park K, Palmer D. Chemotherapy induced hepatotoxicity in metastatic colorectal cancer: a review of mechanisms and outcomes. Crit Rev Oncol Hematol 2013; 88(2): 404-15.
[http://dx.doi.org/10.1016/j.critrevonc.2013.05.011] [PMID: 23786843]
[http://dx.doi.org/10.1016/j.critrevonc.2013.05.011] [PMID: 23786843]
[13]
Tabassum H, Waseem M, Parvez S, Qureshi MI. Oxaliplatin-induced oxidative stress provokes toxicity in isolated rat liver mitochondria. Arch Med Res 2015; 46(8): 597-603.
[http://dx.doi.org/10.1016/j.arcmed.2015.10.002] [PMID: 26562175]
[http://dx.doi.org/10.1016/j.arcmed.2015.10.002] [PMID: 26562175]
[14]
Schwarz JM, Linfoot P, Dare D, Aghajanian K. Hepatic de novo lipogenesis in normoinsulinemic and hyperinsulinemic subjects consuming high-fat, low-carbohydrate and low-fat, high-carbohydrate isoenergetic diets. Am J Clin Nutr 2003; 77(1): 43-50.
[http://dx.doi.org/10.1093/ajcn/77.1.43] [PMID: 12499321]
[http://dx.doi.org/10.1093/ajcn/77.1.43] [PMID: 12499321]
[15]
Santos RD, Gagliardi ACM, Xavier HT, et al. I Diretriz sobre o consumo de gorduras e saúde cardiovascular. Arq Bras Cardiol 2013; 100(1)(Suppl. 3): 1-40.
[http://dx.doi.org/10.5935/abc.2013S003] [PMID: 23598539]
[http://dx.doi.org/10.5935/abc.2013S003] [PMID: 23598539]
[16]
Jung UJ, Choi MS. Obesity and its metabolic complications: the role of adipokines and the relationship between obesity, inflammation, insulin resistance, dyslipidemia and nonalcoholic fatty liver disease. Int J Mol Sci 2014; 15(4): 6184-223.
[http://dx.doi.org/10.3390/ijms15046184] [PMID: 24733068]
[http://dx.doi.org/10.3390/ijms15046184] [PMID: 24733068]
[17]
Pesta DH, Samuel VT. A high-protein diet for reducing body fat: mechanisms and possible caveats. Nutr Metab (Lond) 2014; 11(1): 53.
[http://dx.doi.org/10.1186/1743-7075-11-53] [PMID: 25489333]
[http://dx.doi.org/10.1186/1743-7075-11-53] [PMID: 25489333]
[18]
Grigorian A, O’Brien CB. Hepatotoxicity Secondary to Chemotherapy. J Clin Transl Hepatol 2014; 2(2): 95-102.
[http://dx.doi.org/10.14218/JCTH.2014.00011] [PMID: 26357620]
[http://dx.doi.org/10.14218/JCTH.2014.00011] [PMID: 26357620]
[19]
Lunardelli MJM, Becker MW, Blatt CR. Lesão hepática induzida por medicamentos: qual o papel do farmacêutico clínico? Rev. Bras. Farm. Hosp. Serv. Saúde 2016; 7(4): 31-5.
[20]
Brasil. Ministério da saúde. Conselho Federal de Farmácia - CRF. In: RDC 585 de agosto de 2013, regulamenta as atribuições clínicas do farmacêutico e dá outras providências Brasília, DF. 2013.
[21]
Ise Y, Morita T, Katayama S, Kizawa Y. The activity of palliative care team pharmacists in designated cancer hospitals: a nationwide survey in Japan. J Pain Symptom Manage 2014; 47(3): 588-93.
[http://dx.doi.org/10.1016/j.jpainsymman.2013.05.008] [PMID: 24018207]
[http://dx.doi.org/10.1016/j.jpainsymman.2013.05.008] [PMID: 24018207]
[22]
O’Connor M, Fisher C, French L, Halkett G, Jiwa M, Hughes J. Exploring the community pharmacist’s role in palliative care: focusing on the person not just the prescription. Patient Educ Couns 2011; 83(3): 458-64.
[http://dx.doi.org/10.1016/j.pec.2011.04.037] [PMID: 21621942]
[http://dx.doi.org/10.1016/j.pec.2011.04.037] [PMID: 21621942]
[23]
Tol J, Punt CJ. Monoclonal antibodies in the treatment of metastatic colorectal cancer: a review. Clin Ther 2010; 32(3): 437-53.
[http://dx.doi.org/10.1016/j.clinthera.2010.03.012] [PMID: 20399983]
[http://dx.doi.org/10.1016/j.clinthera.2010.03.012] [PMID: 20399983]
[24]
Pessaux P, Panaro F, Casnedi S, et al. Targeted molecular therapies (cetuximab and bevacizumab) do not induce additional hepatotoxicity: preliminary results of a case-control study. Eur J Surg Oncol 2010; 36(6): 575-82.
[http://dx.doi.org/10.1016/j.ejso.2010.04.010] [PMID: 20452168]
[http://dx.doi.org/10.1016/j.ejso.2010.04.010] [PMID: 20452168]
[25]
Rubbia-Brandt L, Lauwers GY, Wang H, et al. Sinusoidal obstruction syndrome and nodular regenerative hyperplasia are frequent oxaliplatin-associated liver lesions and partially prevented by bevacizumab in patients with hepatic colorectal metastasis. Histopathology 2010; 56(4): 430-9.
[http://dx.doi.org/10.1111/j.1365-2559.2010.03511.x] [PMID: 20459550]
[http://dx.doi.org/10.1111/j.1365-2559.2010.03511.x] [PMID: 20459550]
[26]
Aloia T, Sebagh M, Plasse M, et al. Liver histology and surgical outcomes after preoperative chemotherapy with fluorouracil plus oxaliplatin in colorectal cancer liver metastases. J Clin Oncol 2006; 24(31): 4983-90.
[http://dx.doi.org/10.1200/JCO.2006.05.8156] [PMID: 17075116]
[http://dx.doi.org/10.1200/JCO.2006.05.8156] [PMID: 17075116]
[27]
White RR, Schwartz LH, Munoz JA, et al. Assessing the optimal duration of chemotherapy in patients with colorectal liver metastases. J Surg Oncol 2008; 97(7): 601-4.
[http://dx.doi.org/10.1002/jso.21042] [PMID: 18449915]
[http://dx.doi.org/10.1002/jso.21042] [PMID: 18449915]
Article Metrics
26